<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495597</url>
  </required_header>
  <id_info>
    <org_study_id>EC 124/13</org_study_id>
    <nct_id>NCT02495597</nct_id>
  </id_info>
  <brief_title>LCI and Bronchial Inflammation in Patients With BO</brief_title>
  <acronym>FRABO-02</acronym>
  <official_title>Lung Clearance Index (LCI) and Bronchial Inflammation in Patients With Bronchiolitis Obliterans (BO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators here compare lung function parameters (RV, RV/TLC and FEF75) with the
      results of the Lung Clearance index (LCI) . Further this study evaluates bronchial
      inflammatory markers in 20 patients with bronchiolitis obliterans at the age of 6 to 28 years
      compared with an age- and sex-matched control group. The investigators will perform a
      pulmonary function test (body plethysmography with DLCO) and compare the results with the
      LCI. Further we will measure the fraction of exhaled nitric oxide (FeNO) and draw a blood
      sample to determine the level of systemic inflammation. Finally induced sputum is collected
      and a cell count is performed, and cells and supernatants are analyzed for inflammatory
      markers. This study will set baseline markers for future interventional studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare lung function values with the Lung clearance index of
      20 Patients with Bronchiolitis obliterans aged between 6 up to 28 years. Further we aim to
      compare the bronchial Inflammation between the patients and a reference group with similar
      age conditions to determine possible outcome-parameters for following interventional studies.

      The sputum samples will be processed and quantitatively analyzed to get a profile of the
      cytological composition.

      (Sputum and serum samples are analyzed by quantitative real-time polymerase chain reaction
      (PCR) (qRT-PCR) and by cytometric bead assay (CBA).)

      Methods and Work Programme:

        -  Measurement of nitric oxide in expired air (FeNO)

        -  Lung function testing with spirometry and body plethysmography

        -  Lung clearance index (LCI)

        -  Bronchodilation

        -  Blood test: blood count, CRP, RAST, serum inflammatory mediators, (genetic markers of
           the non-specific pulmonary defense system)

        -  Induced sputum for inflammatory mediators and microbiological investigations
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>LCI compared to RV/TLC%-pred.</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>Correlation of these lung function Parameters in patients with BO compared to healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of sputum cell count over time (percentage of neutrophils)</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>induced sputum will be analyzed for different cellular components such as alveolar macrophages, neutrophils, lymphocytes and others. Epithelial cells will be excluded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of low CrP</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>serum parameter for systemic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC (%-pred.)</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>To compare FVC (%-pred.)of patients suffering from BO with FVC (%-pred.)of a healthy control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 (%-pred.)</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>To compare FEV1 (%-pred.)of patients suffering from BO withFEV1 (%-pred.)of a healthy control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tiffeneau-Index</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>To compare Tiffeneau-Index of patients suffering from BO with Tiffeneau-Index of a healthy control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sRtot (%-pred.)</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>To compare sRtot (%-pred.) of patients suffering from BO with sRtot (%-pred.) of a healthy control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RV/TLC (%-pred.)</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>To compare RV/TLC (%-pred.) of patients suffering from BO with RV/TLC (%-pred.) of a healthy control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 (pg/ml)</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>comparing IL-6 in Serum of patients with BO with healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-8 (pg/ml)</measure>
    <time_frame>during Visit 1 (single day, single observation)1</time_frame>
    <description>comparing IL-8 in Serum of patients with BO with healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-17 (pg/ml)</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>comparing IL-17 in Serum of patients with BO with healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 (mRNA delta-delta-ct)</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>compare IL-6 mRNA in Sputum cells of patients with BO with healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-8 (mRNA delta-delta-ct)</measure>
    <time_frame>during Visit 1</time_frame>
    <description>compare IL-8 mRNA in Sputum cells of patients with BO with healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-17 (mRNA delta-delta-ct)</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>compare IL-17 mRNA in Sputum cells of patients with BO with healthy controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of FOXP3 positive cells in Sputum</measure>
    <time_frame>during Visit 1 (single day, single observation)</time_frame>
    <description>compare percentage of FOXP3 positive cells in Sputum cells of patients with BO with healthy controls</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">37</enrollment>
  <condition>Bronchiolitis Obliterans</condition>
  <arm_group>
    <arm_group_label>Subject-Group</arm_group_label>
    <description>Patients suffering from doctors diagnosed bronchiolitis obliterans</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>age- and sex matched to subject-group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention - just observational</intervention_name>
    <arm_group_label>Subject-Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, sputum cells, sputum supernatans
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from Bronchiolitis obliterans and controls
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  between 6 and 28 years of age

          -  Known Bronchiolitis obliterans

               -  no Bronchiolitis obliterans(depending on the study group)

          -  Ability to perform lung function tests and inhalation

        Exclusion Criteria:

          -  Acute illness with systemic or bronchial inflammation

          -  every chronic condition or infection (eg HIV, tuberculosis, malignancy)

          -  pregnancy

          -  known alcohol and/ or drug abuse

          -  Inability to understand the extent and scope of the study

          -  Participation in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>28 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Rosewich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital, Goethe-University</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/15635614</url>
    <description>Kurland G, Michelson P. Bronchiolitis obliterans in children. Pediatr Pulmonol. 2005 Mar;39(3):193-208. Review</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/16738042</url>
    <description>Smith KJ, Fan LL. Insights into post-infectious bronchiolitis obliterans in children. Thorax. 2006 Jun;61(6):462-3.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/11596161</url>
    <description>Pichler M, Herrmann G, Schmidt H, Ahrens P, Zielen S. Persistent adenoviral infection and chronic obstructive bronchitis in children: is there a link? Pediatr Pulmonol. 2001 Nov;32(5):367-71.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/11106056</url>
    <description>Pichler MN, Reichenbach J, Schmidt H, Herrmann G, Zielen S. Severe adenovirus bronchiolitis in children. Acta Paediatr. 2000 Nov;89(11):1387-9.</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Dr. med. Martin Rosewich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bronchial inflammation</keyword>
  <keyword>Bronchiolitis obliterans</keyword>
  <keyword>Sputum</keyword>
  <keyword>Blood</keyword>
  <keyword>Inflammation</keyword>
  <keyword>adaptive immune system</keyword>
  <keyword>innate immune system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

